Trial Profile
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease, Using Salmeterol as an Active Control.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 29 Jul 2010 Actual end date added to 1 Jul 2010 as reported by ClinicalTrials.gov.
- 29 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2010 New trial record